Pharma Mar, S.A.
PHM
Rank in Stocks
#8009
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and... Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
Share Price
$63.40
Last synced: 2026-11-20
Market Cap
$1.10B
Change (1 day)
-2.39%
Change (1 year)
-27.22%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pharma Mar, S.A. (PHM)
Category
Healthcare
EPS for Pharma Mar, S.A. (PHM)
EPS as of September 2026 TTM: $4.38
According to Pharma Mar, S.A.'s latest financial reports, its current EPS (TTM) is $4.38. At the end of 2025 the company had an EPS of $5.05, an increase over its 2024 EPS of $1.55.
EPS history for Pharma Mar, S.A. from 2002 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $4.38 | -13.34% |
| 2025 | $5.05 | 225.41% |
| 2024 | $1.55 | 2,108.55% |
| 2023 | $0.07 | -97.60% |
| 2022 | $2.93 | -49.90% |
| 2021 | $5.84 | -36.01% |
| 2020 | $9.13 | -1,728.18% |
| 2019 | $-0.56 | 62.75% |
| 2018 | $-0.34 | -80.19% |
| 2017 | $-1.74 | 26.23% |
| 2016 | $-1.38 | -452.62% |
| 2015 | $0.39 | -55.13% |
| 2014 | $0.87 | 5.59% |
| 2013 | $0.83 | 73.74% |
| 2012 | $0.47 | -591.11% |
| 2011 | $-0.10 | -89.21% |
| 2010 | $-0.90 | -59.43% |
| 2009 | $-2.21 | -35.33% |
| 2008 | $-3.41 | -17.17% |
| 2007 | $-4.12 | 13.92% |
| 2006 | $-3.62 | 34.31% |
| 2005 | $-2.69 | -2,655.98% |
| 2004 | $0.11 | -105.33% |
| 2003 | $-1.98 | -10.71% |
| 2002 | $-2.21 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 257.84% |
US
|
|
| $-7.08 | -261.78% |
US
|
|
| $-5.29 | -220.88% |
AU
|
|
| $21.56 | 392.65% |
NL
|
|
| $12.73 | 190.94% |
BE
|
Questions about Pharma Mar, S.A.'s earnings per share (EPS)
What is Pharma Mar, S.A.'s earnings per share (EPS)?
Pharma Mar, S.A.'s earnings per share (EPS) over the last twelve months is $4.38, as of Sep 2026.
What was Pharma Mar, S.A.'s earnings per share (EPS) in 2025?
In 2025, Pharma Mar, S.A.'s earnings per share (EPS) was $5.05, 225.81% more than in 2024 ($1.55).
How has Pharma Mar, S.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Pharma Mar, S.A.'s earnings per share (EPS) went from $9.13 to $5.05, an average decline of 11.17% a year.
How does Pharma Mar, S.A.'s earnings per share (EPS) compare with similar companies?
Pharma Mar, S.A.'s earnings per share (EPS) ($4.38) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.